RenovoRx announces first patient procedure completed in PanTheR study

RenovoRx (RNXT) announced that the first registry-eligible patient procedure in its PanTheR Post-Marketing Registry Study has been successfully completed at the University of Vermont Cancer Center. “We are pleased to be the first site to initiate cancer treatment delivery by RenovoCath in the important PanTheR registry study,” said Dr. Conor O’Neill of the University of Vermont Cancer Center. “This study provides a crucial opportunity to evaluate how RenovoCath can improve drug-delivery in patients diagnosed with solid tumors, while potentially, and importantly, improving survival and quality of life outcomes. By contributing to this registry study, we aim to generate meaningful real-world data that can guide future treatment decisions for patients with difficult-to-treat cancers.”